CXCR5 and prostate carcinoma: (160) proved that recombinant CXCL13 could increase cell proliferation of pAKT and B-cell acute lymphoblastic leukemia (B-ALL), CXCR5/CXCL13 axis might be considered as a prognostic marker and promising target for treating the prostate cancer and B-ALL.